Hepatic Impact of Etrasimod for Treatment of Moderately to Severely Active Ulcerative Colitis: An Integrated Safety Summary From the Etrasimod Ulcerative Colitis Clinical Program

被引：0
|
作者：
Regueiro, Miguel [1 ]
Vermeire, Severine [2 ]
Rubin, David T. [3 ]
Dubinsky, Marla C. [4 ]
Hart, Ailsa [5 ,6 ]
Wu, Joseph [7 ]
Green, Jesse [8 ]
Woolcott, John C. [8 ]
Gorelick, Kenneth J. [8 ]
McDonnell, Aoibhinn [9 ]
Lazin, Krisztina [10 ]
Peyrin-Biroulet, Laurent [11 ,12 ]
机构：
[1] CaseWestern Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH USA
[2] Univ Ziekenhuis Leuven, Leuven, Vlaams Brabant, Belgium
[3] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA
[4] Mt Sinai Kravis Childrens Hosp, New York, NY USA
[5] St Marks Hosp, London, England
[6] Imperial Coll, London, England
[7] Pfizer Inc, Cambridge, MA USA
[8] Pfizer Inc, Collegeville, PA USA
[9] Pfizer Ltd, Sandwich, England
[10] Pfizer AG, Zurich, Switzerland
[11] Lorraine Univ, Last Inserm U954, Vandoeuvre Les Nancy, Lorraine, France
[12] Lorraine Univ, CHU Nancy, Vandoeuvre Les Nancy, Lorraine, France
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1072
引用
收藏
页码：S816 / S817
页数：2
相关论文
共 50 条
  • [31] Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
    Julian Panes
    Anthony Otley
    Yuri Sanchez Gonzalez
    Kristina Fitzgerald
    Wen Zhou
    Dapo Ilo
    Triza Brion
    Muna J. Tahir
    Digestive Diseases and Sciences, 2023, 68 : 2318 - 2332
  • [32] Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
    Panes, Julian
    Otley, Anthony
    Gonzalez, Yuri Sanchez
    Fitzgerald, Kristina
    Zhou, Wen
    Ilo, Dapo
    Brion, Triza
    Tahir, Muna J. J.
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (06) : 2318 - 2332
  • [33] Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12
    Feagan, Brian G.
    Peyrin-Biroulet, Laurent
    Sandborn, William J.
    D'Haens, Geert
    Panes, Julian
    Yarur, Andres
    Wolf, Douglas C.
    Ritter, Timothy E.
    Schreiber, Stefan
    Sloan, Sheldon
    Cataldi, Fabio
    Shan, Kevin
    Rabbat, Christopher J.
    Chiorean, Michael
    Baert, Filip
    Sands, Bruce E.
    Dubinsky, Marla C.
    Vermeire, Severine
    Goetsch, Martina
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S516 - S517
  • [34] A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis
    Law, Cindy C. Y.
    Kayal, Maia
    Mehandru, Saurabh
    Colombel, Jean-Frederic
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 17 (02) : 109 - 117
  • [35] Guselkumab: A New Therapeutic Option for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Bhat, Shubha
    Choi, David
    ANNALS OF PHARMACOTHERAPY, 2025,
  • [36] A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis
    Aoun, Roni
    Hanauer, Stephen
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (05) : 411 - 423
  • [37] Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
    Ernest-Suarez, Kenneth
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [38] Efficacy and Safety of Etrasimod in Patients With Ulcerative Colitis Stratified by Body Mass Index: A Post Hoc Analysis From the ELEVATE UC Clinical Program
    Yarur, Andres J.
    Long, Millie D.
    Torres, Joana
    Nandi, Neilanjan
    Cross, Raymond K.
    Abbatemarco, Arcangelo M.
    Blanco, David
    Niezychowski, Wojciech
    Crosby, Catherine M.
    Wu, Joseph
    Pradeep, Gokul
    Goetsch, Martina
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1026 - S1027
  • [39] Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis
    O'Connell, Jim
    Rowan, Cathy
    Stack, Roisin
    Harkin, Grace
    Parihar, Vikrant
    Chan, Grace
    Breslin, Niall
    Cullen, Garret
    Dunne, Cara
    Egan, Laurence
    Harewood, Gavin
    Leyden, Jan
    MacCarthy, Finbar
    MacMathuna, Padraic
    Mahmud, Nasir
    McKiernan, Susan
    McNamara, Deirdre
    Mulcahy, Hugh
    Murray, Frank
    O'Connor, Anthony
    O'Toole, Aoibhlinn
    Patchett, Stephen
    Ryan, Barbara
    Sheridan, Juliette
    Slattery, Eoin
    Doherty, Glen
    Kevans, David
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (09) : 1019 - 1026
  • [40] ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
    Sandborn, William J.
    Vermeire, Severine
    Peyrin-Biroulet, Laurent
    Dubinsky, Marla C.
    Panes, Julian
    Yarur, Andres J.
    Ritter, Timothy E.
    Baert, Filip J.
    Sloan, Sheldon
    Cataldi, Fabio
    Shan, Kevin
    Rabbat, Christopher J.
    Chiorean, Michael V.
    Wolf, Douglas C.
    Sands, Bruce E.
    D'Haens, Geert
    Danese, Silvio
    Goetsch, Martina
    Feagan, Brian G.
    GASTROENTEROLOGY, 2022, 162 (07) : S1395 - S1395
12345